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The endocannabinoid 
system in sepsis – 
a potential target to improve 
microcirculation?
ABSTRACT
During the last decade, research has identified the endocannabinoid system (ECS) as a key regulator of essential physiolo-
gical functions, including the regulation of microvascular and immune function. Indeed, increasing evidence now suggests 
that release of endocannabinoids and activation of cannabinoid receptors occurs during sepsis and that manipulation of the 
ECS may represent an important therapeutic target to improve microcirculation in sepsis. In this review, the pharmacology 
and physiology of the ECS and the involvement of cannabinoids, cannabinoid receptors and non-CB1R/CB2R pathways 
related to ECS activation will be described. This information will increase our comprehension of the role of lipid signaling 
pathways in sepsis and may lead to the identification of new drug targets for the treatment of impaired microcirculation.
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Introduction
Sepsis, severe sepsis and septic shock 
are the most frequent causes of death 
in surgical intensive care unit patients 
(1) and generate significant costs to 
the health care system. (2) Of partic-
ular concern is the 75% increase in 
the incidence of sepsis that has been 
observed over the last 2 decades. Fur-
thermore, the incidence is projected 
to continue to rise significantly as the 
population ages and the presence of 
co-morbidities also increases. (3,4) 
While there have been some advances 
in the understanding and treatment of 
sepsis, in many cases, despite timely 
intervention, these therapies are unable 
to abrogate sepsis pathophysiology. 
This suggests that the current thera-
peutic approaches and the underlying 
hypotheses guiding treatment for sep-
sis still remain inadequate.
’Cannabinoids from the plant, Cannabis 
sativa, have been widely used in medi-
cine for over a millennium as anticon-
vulsant, analgesic, anti-emetic, anti-
inflammatory and immunosuppressive 
drugs’. (5) The recent interest in canna-
binoids was triggered by the discovery 
of endogenous cannabinoid receptors 
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and their ligands, anandamide and 
2-arachidonoyl glycerol (2-AG). Canna-
binoid-1 receptors (CB1R) exist primar-
ily on central and peripheral neurons, 
their major role is to modulate neuro-
transmitter release, whereas the can-
nabinoid-2 receptors (CB2R) are found 
mainly on immune cells and are known 
to play a role in immune response and 
regulation of inflammatory process-
es. (6) The endocannabinoid system 
(ECS) is upregulated during local and 
systemic inflammation, e.g. sepsis. (7) 
However, the role of the ECS in the 
immune response is still not completely 
known. 
In this review, we will briefly describe 
experimental models to study micro-
circulatory changes during sepsis and 
discuss experimental findings and 
potential clinical approaches to impro-
ve the impaired microcirculation in sep-
sis. Based on general aspects of lipid 
signaling in inflammation and sepsis, 
we will then discuss the pharmacology 
and physiology of the endocannabinoid 
system, involvement of cannabinoids 
and cannabinoid receptors and par-
ticipation of non-CB1R/CB2R pathways 
related to ECS activation.
Experimental models to 
study the microcirculation 
in sepsis
Various experimental models have 
been described to study the microcir-
culation in sepsis. Currently, there are 
two main categories of sepsis models: 
1) toxin models, e.g. endotoxemia and, 
2) bacterial sepsis models, e.g. cecal 
ligation and puncture (CLP).
The toxin models represent acute sep-
tic models and are usually generated 
by direct administration of endotoxin 
intraperitoneally or intravenously. These 
toxin models are widely used to study 
the microcirculation in sepsis beca-
use of their favorable reproducibility 
and similarities to the pathophysiology 
of sepsis. (8) However, the disadvan-
tage of these models is the massive 
and rapid production of inflammatory 
cytokines, which is not comparable to 
clinical patients with sepsis. The diffe-
rences in cytokine response, most likely 
explains why therapeutic strategies that 
might be effective in toxin models are 
not effective in sepsis patients. (9)
Bacterial sepsis models are generated 
by introduction of bacteria into the body 
directly or indirectly. These models are 
chronic and more clinically relevant in 
comparison to toxin models. Bacteri-
al sepsis can be generated by fecal 
pellets, defined bacterial inoculum or 
endogenous fecal contamination as 
described below. (10,11)
1) The fecal pellet models are induced 
by administration of feces plus an adj-
uvant (such as barium) within a pellet. 
The role of adjuvant in this fecal model 
is to prevent rapid clearance of bac-
teria by the host and to modulate the 
mortality rate. (12) The mortality rate in 
this model depends on dose and com-
position of the bacteria in the feces. The 
disadvantage of this model is the varia-
tion in the amount of bacteria and spe-
cies between feces samples resulting in 
inconsistent sepsis severity. (13)
2) The defined bacterial inoculum 
models are very similar to the fecal 
pellet models. The only difference is 
that the bacterial population is defined 
in this model. Generally, Escherichia 
coli (E.coli) is the strain of bacteria that 
is mixed with sterilized cecal contents 
and given to the peritoneum. (14) The 
main advantage of this model is that the 
mortality rate is controllable by modi-
fying the dose of E. coli.
3) Endogenous fecal contamination can 
be achieved by at least two models. In 
the CLP model the cecum is ligated and 
punctured with a needle. The advanta-
ge of this model is that the mortality rate 
can be modulated by the size of the 
needle used and the number of punctu-
res made in the cecum. However, the 
disadvantages of this model are that 
animals are in general not fluid resus-
citated and do not receive antibiotics. 
(15) A second type of fecal contamina-
tion is the Colon Ascendens Stent Peri-
tonitis (CASP) model in which a stent 
with a defined diameter is placed into 
the ascending colon, allowing feces to 
reach the peritoneal cavity continuou-
sly. Compared to CLP the advantage 
of the CASP model is having a secured 
continuous fecal contamination and 
controllable mortality rate by modula-





The main role of microcirculation is to 
provide oxygen and nutrients to the 
tissue cells. Impairment of microcircula-
tion represents a key event in the pathop-
hysiology of sepsis. (17) Using intravital 
videomicroscopy (IVM), a method that 
has been widely used to visualize the 
dynamical changes of microcirculation 
in vivo, researchers have demonstrated 
that alterations of the microcirculation, 
including a decrease in perfused capi-
llary density and an increase in spatial 
heterogeneity of perfused capillaries, 
occurs in sepsis. (18) In a CASP-indu-
ced sepsis, microcirculation alteration 
started about 12 hours after insertion 
of a 16G stent, expressed by increa-
sed number of rolling and adhering 
leukocytes in small blood vessels, and 
reached significant differences at 18 h 
compared to control animals. However, 
there were no significant changes on 
the functional capillary density. (16) 
Using an endotoxemia model of sepsis 
we demonstrated that LPS administrati-
on decreases the rolling flow, increases 
the number of adhering leukocyte (more 
pronounced than in the CASP model of 
sepsis) and reduces functional capillary 
density in muscular and mucosa layers 
of the intestinal wall. (19) To compare 
the impact of different types of shock 
(septic vs. hemorrhagic) on microcir-
culation, Nencioni et al. demonstrated 
that the septic group of animals had 
more pronounced alterations in the 
microcirculation in comparison to the 
hemorrhagic group. (20)
The microcirculation in human sepsis 
can also be evaluated by video-micros-
copic techniques such as orthogonal 
polarization spectral (OPS) and side-
stream dark-field (SDF). (17,19) Both 
techniques are based on the applica-
tion of different wavelength lights to 
the tissue, with the reflection of light 
providing images from microvascular 
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vessels. (21) In a study by Chierego et 
al. (22) the OPS technique was used in 
50 subjects (severe sepsis patients vs. 
healthy volunteers). The observations 
showed a significant decrease in the 
proportion of perfused vessels, from 
90% to 48% in septic patients compa-
red to control patients. (21,22)
Changes in microcirculation are com-
monly seen in critically ill patients, 
especially sepsis patients. Therefore, 
monitoring the changes in microcircu-
lation could contribute to the diagnosis 
of sepsis and to the identification of 
therapeutic strategies to improve the 
outcome of microcirculatory dysfuncti-
on in septic patients.
Therapeutic approaches 
to improve the 
microcirculation in sepsis
According to the guidelines for the 
management of severe sepsis and sep-
tic shock, recommended therapies for 
the treatment of sepsis include: Initial 
resuscitation, antibiotic therapy, fluid 
therapy, vasopressors, corticosteroids, 
and recombinant human activated pro-
tein C. (23) However, no specific thera-
pies are approved to treat the impaired 
microcirculation in sepsis. The lack of 
proven therapies is mainly due to the 
difficulties in measuring the impact of 
potential beneficial treatments on the 
microcirculation in humans. 
Nevertheless, numerous approaches 
to improve the microcirculation in sep-
sis have been studied. The spectrum 
of agents tested includes: Vasoactive 
drugs (e.g. dopexamin), oxygen free 
radical scavengers (e.g. aminostero-
ids), anti-inflammatory drugs and anti-
coagulants. (20,24-26) Also, several 
antibiotics which possess vasoactive 
and anti-inflammatory properties may 
ameliorate decrements in microcircu-
lation function.  (27) Another approach 
is the use of different crystalloid and/
or colloid fluids. (28,29) Last but not 
least, tight blood glucose level control 
has been shown to be beneficial for the 
septic microcirculation. (30)
Despite improvements of treatment with 
the described recommended appro-
aches, microcirculatory therapies still 
remain unsatisfactory; new drug trea-
tments aimed at identifying receptors 
and downstream signaling pathways 
during the first stages of severe sepsis 
is an area that is attracting attention for 
the development of newer agents that 
can be included in the drug treatment 
arsenal for sepsis patients.  
Recently, considerable interest has 
been shown in the involvement and 
manipulation of endogenous lipid 
signaling pathways in sepsis progre-
ssion and treatment. (31) Among can-
didate lipid signaling pathways, eviden-
ce suggests that the ECS may play a 
pivotal role in immunomodulation and 
microvascular regulation and therefore 
may be a therapeutic target in the trea-
tment of sepsis.
General aspects of lipid 
signaling in inflammation 
and sepsis
Inflammatory reactions generally have 
a protective role in the body. In fact, 
acute inflammation is the response of 
the host to an infection or injury, and is 
orchestrated by neutrophil recruitment 
to the site of inflammation. (32) Un-
controlled inflammation is the cause 
of many diseases such as atheroscle-
rosis, asthma, cancer and sepsis. (32) 
Inflammatory reactions must be resol-
ved to prevent the spreading of acute 
inflammation to become chronic or 
cause disease. There is a growing body 
of evidence that inflammation and infla-
mmatory disorders, including sepsis, 
could be modulated by endogenous 
chemical signaling molecules such as 
lipid mediators. The fundamental role 
of lipid mediators is regulating resolu-
tion of inflammation through activation 
of anti-inflammatory and pro-resolving 
signaling pathways. The arachidonate-
derived eicosanoids, lipoxins, are the 
first recognized lipid mediators (LMs) 
that have the dual properties of anti-
inflammation and pro-resolution. (32) 
Lipoxins reduce the entry of neutrophils 
to the site of inflammation, and increase 
the uptake and clearance of apoptotic 
neutrophils by macrophages. (33) The 
resolution function of lipoxins is media-
ted through activation of macrophages 
to initiate macrophage phagocytosis 
of the apoptotic neutrophil. (32) Anot-
her potential therapeutic application 
that lipid mediators such as lipoxins 
may have for the treatment of sepsis 
is their ability to block secretion of TNF 
by directly affecting human T-cells. (33) 
Given that blocking pro-inflammatory 
cytokine production is one potential 
approach for treatment of sepsis, iden-
tification of lipid signaling pathways that 
mediate anti-inflammatory actions is a 
key area of investigation. 
In addition to lipoxins, the endocanna-
binoid system is upregulated during 
local and systemic inflammation such 
as sepsis. Endocannabinoids are rele-
ased in response to inflammatory sti-
muli and their levels are elevated in the 
patients and animals with septic shock. 
Endocannabinoids are arachidonic 
acid derivatives and part of the bioacti-
ve lipid signaling system. Identification 
of the role of endocannabinoids in tre-
atment of uncontrolled inflammatory 
diseases such as sepsis may reveal 




Research on the marijuana plant, Can-
nabis sativa, started in the 19th century. 
Cannabis sativa, which contains more 
than 60 active phytocannabinoids, is 
one of the oldest plants to be used 
for medical purposes including, as 
an analgesic, and in the treatment of 
obesity and cancers. Cannabinoids 
mediate their effects through binding 
to specific receptors, members of the 
G protein coupled receptor (GPCRs) 
superfamily. In 1990 Matsuda et al. (34) 
cloned the CB1R and in 1993, Munro 
et al. (35) identified the CB2R. CB1Rs 
are expressed in the central nervous 
system (CNS), especially in the brain, 
and have a role in regulation of syn-
aptic transmission. CBR2 are mainly 
expressed on immune cells and activa-
tion of CB2R affects immune responses 
and inflammatory reactions. (36) Fur-
ther investigation of CB2R expression 
showed that these receptors are not 
just restricted to the periphery but found 
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in select areas of the brain and in the 
gastrointestinal (GI) system. (37) The 
primary research focus of CB2Rs is 
their role in the immunological function 
of leukocytes. Accumulating experi-
mental data has provided convincing 
evidence that modulation of the CB2R 
is a good target for treatment of inflam-
matory diseases. (38)
The ECS is an endogenous lipid signal-
ing system. The ECS consists of can-
nabinoid receptors (CB1R and CB2R), 
endogenous ligands for these receptors 
(endocannabinoids), and the enzymes 
that are required for synthesis and inac-
tivation of endocannabinoids. (36) Can-
nabinoids, the ligands for cannabinoid 
receptors, are divided into three main 
classes: Phytocannabinoids (cannabis 
derivatives), synthetic cannabinoids 
and endogenous cannabinoids (endo-
cannabinoids). 9-tetrahydrocannabi-
nol (THC), cannabidiol (CBD) and can-
nabinol (CBN) are the most well known 
phytocannabinoids. (37) The Cannabis 
plant contains cannabinoids with vary-
ing pharmacological effects; THC is 
mainly associated with the behavio-
ral effects of Cannabis sativa, but is 
also known to be analgesic and neuro-
protective. (5) The phytocannabinoid, 
CBD, lacks psychoactive actions but is 
known to reduce inflammation, convul-
sion, anxiety and nausea. CBN is anoth-
er component from the cannabis plant. 
It acts as a weak agonist of CB1R and 
CB2R and lacks the behavioral actions 
of THC. (37) Endocannabinoids are the 
body’s natural agonists for cannabinoid 
receptors. In fact, endocannabinoids 
are members of the eicosanoid super 
family and are able to activate cannabi-
noid receptors. (39) The two most well 
known endocannabinoids are ananda-
mide (AEA) (40) and 2-arachidonoyl 
glycerol (2-AG) (41) both of which func-
tion as neurotransmitters in the CNS 
and periphery. Anandamide binds to 
CB1Rs but can also bind to a lesser 
extent to CB2Rs. 2-AG binds with the 
same affinity to CB1R and CB2R and 
acts as a full agonist at both receptors. 
(5) Moreover, 2-AG and Anandamide 
are both  synthesized “on demand” 
through multiple biosynthetic pathways. 
(42) In addition to endocannabinoids 
and plant phytocannabinoids, synthetic 
cannabinoids, derived through labora-
tory synthesis, are also available and 
exert their pharmacological actions by 
binding to either CB1R or CB2R, or both 
receptors. (37) Cannabinoid receptors 
activate multiple signaling pathways 
including preferential activation of Gi 
proteins, inhibition of adenyl cyclase 
(AC) and reduction in cAMP accumu-
lation, and activation of mitogen acti-
vated protein kinase pathways in most 
tissues. (43) In the nervous system, 
CB1R activation results in inhibition of 
voltage-dependent calcium channels, 
as well as both activation and inhibi-




The ECS plays an important role in 
immune system modulation and incre-
asing evidence supports upregulati-
on of the ECS during both local and 
systemic inflammation, e.g. sepsis. 
Endocannabinoids are released from 
macrophages, dendritic cells, platelets 
and parenchymal cells in response to 
inflammatory stimuli and oxidative stre-
ss, and are present in elevated levels 
in the sera of patients and animals in 
septic shock. (43,44)
Examination of CBR function has reve-
aled that CB2R are present on macrop-
hages, neutrophils and lymphocytes 
and activation of these receptors has 
been generally associated with anti-
inflammatory effects including reduced 
macrophage and neutrophil numbers 
at the site of infection and decreases 
in pro-inflammatory cytokines. (45) The 
use of CB2R agonists in experimental 
models of moderate sepsis reduced 
the continued recruitment of neutrop-
hils to the site of infection, while incre-
asing phagocytosis and clearance of 
bacteria. (46) Conversely, in severe 
sepsis where neutrophil recruitment 
and function can be detrimental to the 
host through increased tissue damage 
and cardiac death early in the septic 
course, CB2R inactivation reduced 
mortality. (47)
With respect to the contribution of CB1R 
to inflammation and sepsis, several stu-
dies suggested that activation of CB1R 
located on the presynaptic terminals of 
autonomic nerves or the vascular walls 
may contribute to the hypotension asso-
ciated with septic shock. (48) However, 
the contribution of CB1R in this action 
was called into question, when LPS still 
produced an acute hypotension res-
ponse in mice genetically lacking both 
CB1R or CB1R/CB2R. (49)
Our group studied the effects of ECS 
modulation on the microcirculation in 
experimental endotoxemia and CASP-
induced sepsis. We found that in endo-
toxemia, reciprocal activation of the 
ECS might be of benefit; stimulation of 
CB2R by HU308 reduced inflammation 
and improved microcirculatory para-
meters, inhibition of CB1R by AM281 
was protective in the intestinal and the 
iridal microcirculation in experimen-
tal endotoxemia. (50,51) However, 
following 16 hours of CASP-induced 
experimental sepsis and treatment 
with the CB1R agonist, ACEA, leuko-
cyte adhesion was reduced, whereas 
CB2R stimulation did not affect leu-
kocyte adhesion. CB2R inhibition by 
AM630, however, significantly reduced 
leukocyte activation and restored capi-
llary perfusion. (52)
Taken together, the evidence sugge-
sts that release of endocannabinoids 
and activation of cannabinoid receptors 
occurs during sepsis and that mani-
pulation of the ECS may represent an 
important therapeutic target in mana-
ging sepsis and septic shock. 
Non-CB1R/CB2R pathways 
involved in ECS activation
It has been recognized that endoca-
nnabinoids, phytocannabinoids and 
synthetic cannabinoids can activate 
receptors other than CB1R and CB2R. 
(45) Best known of the non-CB1R/
CB2R cannabinoid-related receptors 
is the transient receptor potential vani-
lloid subfamily, member 1 (TRPV1). 
(53) This receptor is a ligand-gated 
cation channel that is a member of a 
superfamily of ion channels that also 
includes “classical” transient receptor 
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potential channels (TRPC), transient 
receptor potential melastatin channels 
(TRPM) and transient receptor poten-
tial ankyrin (TRPA) channels. (54) 
TRPV1 is found on sensory nerves and 
plays an important role in the transmi-
ssion of pain. The endocannabinoid, 
AEA has been demonstrated to bind 
to this receptor, resulting in channel 
deactivation and analgesia. (55) In 
addition to TRPV1, TRPV2, TRPA1 and 
TRPM8 also respond to cannabinoid 
ligands. (45)
The orphan G protein coupled recep-
tors, GPR55 and GPR18, are both acti-
vated by a variety of exogenous and 
endogenous cannabinoids and lipids, 
including the cannabidiol analogue, 
abnormal cannabidiol (abn-CBD), AEA 
and N-arachidonoyl glycine.  Both 
GPR55 and GPR18 have been sug-
gested as candidate receptors for the 
abn-CBD-sensitive cannabinoid-rela-
ted receptor that mediates hypoten-
sion and alterations in macrophage 
activity. (56,57)
Conclusions
In summary, inflammatory diseases, 
including sepsis, are characterized by 
pathological changes within the micro-
circulation. (58) Long-lasting impair-
ment of the microcirculation causes 
severe decrements in tissue perfusion 
and organ function and plays a key role 
in the progression to severe sepsis. (58) 
Given the complex pathophysiology of 
systemic inflammation and the high 
mortality associated with severe sepsis, 
identifying novel drugable targets and 
appropriate therapeutic windows is a 
priority for treating this disease. 
During the last decade, research has 
identified the ECS as a key regulator 
of essential physiological functions, 
including the regulation of microvas-
cular and immune function. Indeed, 
increasing evidence now suggests that 
release of endocannabinoids and acti-
vation of cannabinoid receptors occurs 
during sepsis and that manipulation of 
the ECS may represent an important 
therapeutic target in managing sepsis 
and septic shock. However, in order 
to move these findings into the clinic, 
it still remains essential to provide a 
more comprehensive understanding 
of ECS activity during sepsis. This will 
require further examination of: 1) ECS 
function in relevant experimental mod-
els of inflammation and sepsis using 
appropriate techniques, such as IVM. 2) 
Identification of target receptor proteins 
(both cannabinoid and non-cannabi-
noid receptors) involved in mediating 
the actions of cannabinoids and endo-
cannabinoids in both immune cells and 
microvasculature. This information will 
increase our comprehension of the role 
of lipid signaling pathways in inflamma-
tion and may lead to the identification of 
new drug targets for treating sepsis.
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